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Problem: Safety concerns have existed for more than 40 years about how hazardous drug (HD) 
exposure contributes to long- and short-term adverse health outcomes for healthcare workers 
(HCWs). Careless handling may cause toxic residues to infiltrate hospital environments and 
patient care areas, and can even be traced to patients’ homes. New government regulations will 
require healthcare organizations to minimize exposure risks to HCWs by fully implementing the 
U.S. Pharmacopeia (USP) Convention Chapter 800: Hazardous Drugs: Handling in Healthcare 
Settings (USP, 2016) on December 1, 2019. According to Polovich and Olsen (2017), “The 
implementation of the USP <800> Standards will represent an important step forward for nurses 
and other potentially exposed HCWs” (p. 1). 
Context: The proposed Doctor of Nursing Practice (DNP) project will implement an HD safe-
handling personal protective equipment (PPE) toolkit at an ambulatory cancer infusion center to 
improve nurses’ adherence with the USP <800> Standards and hospital policies addressing PPE 
use when handling, administering, and disposing of HD. 
Proposed Interventions: Interventions for this project will consist of (a) an HD safe-handling 
PPE toolkit for infusion nurses, (b) a PPE observation tool, (c) an expert panel discussion, (d) a 
nurses’ skills session, (e) safe-handling adherence between observation and self-assessment 
survey, (f) hazardous drug administration safe handling peer-to-peer checklist, and (g) a 
performance dashboard to display progress.  
Proposed Outcome Measures:  Outcome measures include (a) 90% or higher compliance rates 
with PPE use and (b) sustained adherence to USP <800> Standards and hospital policies for safe 
HD handling to 100% by February 2020. 
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Section II: Introduction 
 
Problem Description  
Healthcare organizations are preparing for the implementation of the USP Chapter 800: 
Hazardous Drugs-Handling in Health Care Settings (USP <800>), where regulatory standards 
will provide enforceable safe-handling protections for all HCWs to minimize HD exposure risks 
(USP, 2016). As USP <800> changes how HDs are managed, organizational efforts to educate 
staff and ensure acceptance from HCWs will drive new worker safety protections (Andrews & 
Dill, 2018). Despite scientific evidence of known exposures and adverse health outcomes related 
to residue exposure, resistance to the use of PPE or other safe-handling measures during 
preparation, administration, and waste disposal continue among infusion nurses. Adverse health 
outcomes may include genetic changes, developing certain cancers, birth defects and fetal 
abnormalities, organ toxicity, and infertility, among others.  According to Hennessy and Dynan 
(2014), “Resistance is based on the denial of risk, insufficient information, lack of policy 
enforcement or regulation, or lack of provision of safe-handling devices” (p. 497).  
  Infusion nurses have not well received policy efforts to change from recommended PPE 
guidelines for HD administration to mandatory requirements. Studies have shown that nurses’ 
PPE use is inconsistent across the country. The primary focus for implementing this evidence-
based practice (EBP) initiative is two-fold: (a) USP <800> requires HCWs to wear proper PPE 
when handling HDs, and (b) nurses need to consistently adhere to USP <800> standards and 
organizational policies during patient care. The proposed quality improvement (QI) intervention 
is of interest to the organizations’ “Environment of Care” Workstream Committee whose 
purpose is to prepare ambulatory health care units for compliance with USP <800> Standards. 
The outcomes are of interest to the organizations’ Cancer Committee because it satisfies the 
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“Quality Improvements” Standard 4.8 of the Commission on Cancer Program accreditation 
requirements.  Until recently, the organization’s efforts have been placed on developing inpatient 
compliance, with minimal attention paid in ambulatory care settings. To address infusion nurses’ 
reluctance to wearing PPE, the organization must understand how it contributes to this 
phenomenon, eliminate barriers to allow for best practice, and implement changes to improve 
safety and compliance. 
The setting will be an ambulatory infusion center (AIC). The AIC has 36 infusion 
treatment chairs available for chemotherapy and non-chemotherapy patients. The study will 
involve the observation of experienced infusion nurses, defined as having two or more years of 
experience in chemotherapy administration, to determine the baseline compliance rate of PPE 
use with HD handling. All nurses are required to possess a chemotherapy and biotherapy 
certification card that demonstrates sufficient training and competence in the area of HD 
administration processes and drug knowledge. The first goal is to observe at least 90% of the 
nurses prepare, administer, and dispose of HDs over a four-week period.  Fifteen nurses are 
eligible to participate in the quality improvement (QI) project. At the organization where the 
project will be implemented, policies specific to PPE requirements with HD handling are 
currently under review and revision. However, the Oncology Nursing Society (ONS) states that 
standard-specific gloves (ASTM D6978), non-permeable gowns, face masks and eye shields (or 
goggles), and respirator masks be readily available for PPE use at a minimum. The project will 
follow the ONS guidelines for PPE use with HD handling until policies have been approved for 
the infusion center. 
 
Available Knowledge 
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Hazardous drug residues pose a real threat to the health and wellbeing of staff, patients 
and families, and the environment when left uncontrolled or mismanaged. The National Institute 
for Occupational Safety and Health (NIOSH, 2016) reported more than eight million HCWs in 
the United States are potentially exposed to HDs. Furthermore, HCWs with long-term, low-level 
occupational exposure have shown an increased risk of adverse reproductive outcomes and other 
unwanted health issues (Connor, Lawson, Polovich, & McDiarmid, 2014; Hon, Teschke, Shen, 
Demers, & Venners, 2014). McDiarmid and Condon’s (2005) research identified a 20% increase 
in chromosomal abnormalities of HCWs who had a ‘moderate’ level of hazardous drug handling 
(>100 handling events of chemotherapy within six weeks). Lack of diligent organization and 
worker accountabilities, inconsistent oversight, and environmental exposure have caused 
irreversible harm and death in some cases (Smith, 2010). Toxic residues found on common 
healthcare surfaces may spread to patient homes, exposing cohabitants, family pets, and the 
environment (Bohlandt, Sverdel, & Schierl, 2017; Connor, Zock, & Snow, 2016; Yuki, Sekine, 
Takase, Ishida, & Sessink, 2013). 
 
PICOT Question 
Would the development of an HD safe-handling PPE toolkit improve infusion nurses’ 
compliance and adherence with PPE use during HD handling and comply with USP <800> 
standards and hospital policies for HD safe handling by February 1, 2020? 
Literature Review 
I conducted a literature review using CINAHL, Cochrane Library, and PubMed databases 
to locate current information on the health hazards of residue exposure and recent EBP 
recommendations to improve PPE use in nurses. More than 50 articles from 2005 to 2019 were 
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located in the database search, with 15 selected for further review. Findings demonstrated a clear 
and present danger regarding HD exposure and the need to implement mandatory EBP policies 
for PPE use and environmental oversight. Excluded articles were those that focused on hospital 
HD administration, routes of administration other than intravenous (IV), anesthesia HDs, and 
occupations outside the healthcare setting. Keywords for the search included hazardous drugs, 
occupational health, protective equipment, safety standards, and USP <800>. Final literature 
selection criteria were determined after analyzing the strengths, weaknesses, limitations, and 
quality of evidence using the Johns Hopkins Nursing Evidence-Based Practice Tool (Dearholt & 
Dang, 2016). There were five Level IA, four Level IIA, and six Level IIIA quality ratings for the 
selected articles, which represents a quality approach for selecting the evidence for this project.  
A summary of the evidence is available in an evaluation table (see Appendix B). The articles and 
research studies identified three themes: (a) HD residues found in patient homes after treatment, 
(b) organizational responsibilities, and (c) nurses’ responsibilities to practice and provide safe 
care for others, including the environment of care. 
Hazardous drug residues found in patient homes. Yuki et al. (2013) tested the urine of 
family members of three cancer patients who received at least one of two antineoplastic drugs 
(cyclophosphamide [CP] and fluorouracil [5-FU]) during the first 48 hours after IV 
chemotherapy treatment. The objectives were to determine if (a) any detectable levels of HD 
agents exposed family members, (b) whether environmental contamination occurred inside the 
home, and (c) how long a drug remained in the patient’s urine 48 hours after treatment. Urine 
samples were collected from patients and patient family members, and swipe tests were obtained 
from common home surface areas to detect if CP or 5-FU residues were present. Predetermined 
acceptable drug levels for CP were 0.01 and 5ng/ml urine for 5-FU. Cyclophosphamide was 
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detected in eight of 12 swipe tests (0.03 – 7.34 ng/cm2) in one of the homes. Swipe tests in 
homes of treated patients with 5-FU reported drug levels below the predetermined threshold; 
however, there are currently no defined acceptable levels of HD exposure. 
Swipe tests from toilet seats and bathroom sink faucets had the highest level of HD 
residue (3.02 and 0.57 ng/cm2); floors around toilets and bathroom doorknobs measured 0.03 
and 0.09 ng/cm2. Most importantly, patients continued to excrete antineoplastic drugs at low 
levels over more than four days through urine, feces, and standard breathing patterns. Family 
members who handle potentially contaminated waste products, such as urine, stool, vomit, or 
other excreta, should receive specific safe-handling instructions to control the spread of 
contaminants in the home setting. While most research focused on controlled health 
environments, it is imperative that patients receiving HDs be better informed and prepared in 
case of potential exposure situations to families and friends. 
Bohlandt et al. (2017) conducted an environmental and biological study inside 13 homes 
of treated cancer patients to confirm potential HD residues on household surfaces. The 
researchers wanted to determine whether HD levels were measurable in the cohabitants of 
treated patients. Thirteen study participants received outpatient IV chemotherapy in an oncology 
infusion clinic. The researchers obtained 265 samples from home surfaces, including bathroom 
toilets, floor and sink handles, and kitchen surfaces. Every specimen had substantial levels of HD 
residues, but cohabitant urine samples did not detect any trace of IV chemotherapy residues. 
Crickman and Finnell’s (2016) systematic literature review covered 13 years of articles, 
from 1979 to 2014, to understand the need to implement HD control measures in different 
settings. Healthcare workers, especially those who are not responsible for medication 
administration but clean up after a treated patient, are among the highest at-risk population. The 
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findings are worrisome because families often become primary caregivers after chemotherapy 
treatment. Recommendations regarding PPE selection and choice, HCW competencies, increased 
professional oversight, and medical monitoring of high-risk staff will be mandated requirements 
in the USP <800> regulations. These articles indicated that HCWs must also practice safe 
handling in controlled settings to minimize personal risk; they must also educate and inform the 
public.   
Organizational responsibilities. Clark, Zickar, and Jex (2014) developed a field study 
investigating the influence of role definitions on the association between safety climate and 
employees’ organizational citizenship behavior. Providing safe working conditions requires a 
significant commitment on the part of leadership and stakeholders. Unfortunately, an 
organizations’ obligation to provide safe, patient-centered care often overshadows or conflicts 
with ensuring that staff also deserves safe working conditions to provide that care. For example, 
scheduling patients for infusion therapy requires an acuity-based, decision-making process, yet 
nurses are often scheduled to treat far more patients than is safe with HD administration. Clark et 
al. stated that nurses who feel appreciated, protected, and respected by their organization are 
more likely to go above and beyond expectations to provide optimal patient care. 
In 2017, He, Mendelsohn-Victor, McCullagh, and Friese completed a cross-sectional, 
multi-state survey offered to Oncology Nursing Society (ONS) members (N = 654) to examine 
whether the organization’s safety culture correlates to nurses’ use of PPE. The study involved 
nurses working in ambulatory care centers in three states across the United States; 67% of the 
oncology nurses responded to the survey. One tool used to collect data was the Revised 
Hazardous Drug Handling Questionnaire (Martin & Larson, 2003; Polovich & Olsen, 2017). The 
sample mean for the PPE-use score was 2.4 (SD = 1.0) out of a maximum score of 5.0. 
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Nurses self-reported that 26% were involved in an HD spill, 90% wore only one pair of 
chemotherapy-approved gloves, and other PPE supplies were infrequent. He et al. (2017) found 
that if nursing workloads increased by one patient, the odds of an HD spill increased by 3.0% 
(OR = 1.03, 95% CI [1.01 – 1.06], p = 0.01). He et al. recommended that nurse managers 
monitor and adjust patient acuity, ensure that PPE is readily available, and provide ongoing HD 
training to prevent adverse events. Furthermore, the authors stressed the need for organizations 
to commit to a culture of safety that may include modifying the nurses’ workload and 
environment, if necessary, to accommodate safe-handling practices and self-protection during the 
HD-handling process (He et al., 2017). 
Nurses’ responsibilities to provide safe care. The most recent study by Friese, Yang, 
Mendelsohn-Victor, and McCullagh (2019) concluded that despite decades of research, PPE use 
remains suboptimal and that professional organizations, policymakers, clinical experts, and 
healthcare systems align to guide best practices to ensure public safety. The randomized 
controlled study, from 2015 to 2017, involved 12 academic healthcare ambulatory oncology 
centers across the United States and included nurses who handled HDs (N = 396). All data were 
collected from a secure website where participants accessed learning modules and completed 
questionnaires to self-report PPE use. The intervention did not improve adherence among 
participants. Therefore, the authors suggested that nurse leaders standardize education and HD 
policies and procedures and enforce personal accountability regarding safe-handling steps and 
PPE use (Friese et al., 2019). Under USP <800>, efforts to provide oversight and safe handling 
across oncology settings will no longer be considered recommendations or guidelines. 
DeJoy et al. (2017) examined predictors of PPE use, safe-handling components, and 
adverse events associated with HD exposure in nurses (N = 1,814) and concluded that adherence 
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to recommendations is inconsistent. Interestingly, PPE use was worse and less predictable among 
more experienced nurses during chemotherapy administration than among their less experienced 
colleagues. The study assessed organizational safety climate and nurses’ perceived safety climate 
regarding PPE, engineering controls, and adverse events associated with IV HDs. DeJoy et al. 
found that nurses’ perceptions about exposure risks were low and that they understood 
organizational policies to merely be guidelines for PPE use. A comprehensive health and safety 
program emphasizing hazard controls is critical to promote safer behavior among all HCWs. 
Summary of the Evidence 
The literature review suggests that HD controls are inconsistent and that workplace 
contamination may lead to HCW and patient exposure to toxic agents. Both international and 
national research conducted in ambulatory oncology practices support stricter, even mandatory, 
PPE utilization and endorse environmental and biological monitoring for the detection of 
harmful residues, similar to radiation exposure monitoring of HCWs (Bohlandt et al., 2017; 
Boiano, Steege, & Sweeney, 2014). Summaries from the literature review reveal gaps in safety 
controls. Researchers concluded with recommendations for HD controls that focus on (a) better 
engineering controls, such as closed-system transfer devices (CSTDs) and biologic safety 
cabinets; (b) administrative controls, such as updating policies and procedures and improving 
access to information; (c) work practice controls, such as acuity-based scheduling and reducing 
workloads and crowded spaces; and (d) ensuring the mandatory use of PPE. Furthermore, nurses 
are aware of the hazards associated with exposure but continue to exhibit risky behavior. 
Rationale/Conceptual Framework 
The Orem model of nursing or self-care deficit nursing theory was developed by nursing 
theorist Dorothea Orem and covers a broad spectrum of general concepts for nursing 
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consideration and application (Alligood, 2014). The theory is comprised of three related parts: 
(a) the theory of self-care, (b) the theory of self-care deficit, and (c) the theory of nursing 
systems. Some of the theory’s relativity to this project include: a person’s knowledge of potential 
health problems is needed for promoting self-care behaviors, the prevention of hazards to human 
life and wellbeing, and responsibility for their care, as well as others who require care (Vincent, 
Pischke-Winn, Pakieser-Reed, & La Fond, 2016). This model depicts how health professionals 
have as much of a responsibility to care for themselves as they would care for others (Younas, 
2017). 
Donabedian’s conceptual model, developed in 1966, provides a framework for 
developing, implementing, and evaluating this intervention (McDonald et al., 2007). Applying 
the components of the model to this project include the assessment of structures, processes, and 
outcomes relative to ambulatory oncology infusion centers associated with the management and 
safe handling of chemotherapeutic agents. According to Donabedian, the physical setting would 
be determined as the Cancer Center’s AIC. The elements would include the mission and values 
of the organization, leadership skills, staff knowledge levels, adequate staffing and scheduling, 
suitable workspace, and patient population. Other elements to support a safety culture include 
having access to HD waste bins, chemotherapy spill kits, and CSTDs. 
The process includes interventions that occur within the AIC that contribute to the 
outcomes of safe drug delivery, such as HD administered by oncology trained nurses. 
Developing standard work and tip sheets that outline the responsibilities and steps for each stage 
in the HD-handling process, including any associated interdisciplinary tasks, are aspects of 
process outcomes. Evidence-based guidelines and regulatory mandates specific to HCWs and 
patient safety are specified in the USP <800> Standards. 
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Finally, an outcome is the final product combining both structure and process. A 
favorable outcome would have a sustainable structure and process that reduces the risk of HD 
contamination at all stages of handling. Poor outcomes allow for failures, such as inconsistent 
use of PPE by nurses or other processes contrary to EBP recommendations. Different relevant 
outcomes include improved patient perception of safety scores from Press Ganey surveys and 
reduced costs due to employee health matters related to HD exposure. Nurses’ attitudes and 
perceptions about protecting themselves to protect others will align with policies and procedures 
and other best practice initiatives and comply with the USP <800> Standards. 
Specific Aims 
The objectives are to develop, implement, and evaluate an HD safe-handling PPE toolkit 
to learn if infusion nurses’ adherence to PPE use will improve to 100% with HD handling and 
comply with the USP<800> standards and hospital policies for safe handling by February 2020. 
The specific aims of the project are to determine if (a) based on direct observation, nurses 
comply with USP <800> requirements and hospital policies for HD handling when administering 
and disposing of IV chemotherapy (as defined in the PPE toolkit); (b) based on nurse self-
assessment, PPE standards and hospital policies for safe handling were followed at least 90% of 
the time; and (c) any differences are noted in nurses observed and self-assessed adherence to 
PPE standards and hospital policies for safe handling.  If differences are noted, additional peer-
to-peer coaching will be considered until 90% compliance has been reached. 
 
USP <800> AND THE PPE PROJECT   15 
 
Section III: Methods 
Context 
Personal protective equipment use has been defined in the literature as a critical element 
required for handling HDs at any step in the process. The administration process for ambulatory 
infusion nurses to safely administer HDs will require enhanced training on selecting, donning 
and doffing PPE, and proper disposal of contaminated equipment. According to Friese et al. 
(2019), “Education and engagement of nursing personnel are not sufficient to improve PPE use. 
However, systematic approaches may result in improved practice” (p. 255). The proposed 
intervention will include the development of an HD safe-handling PPE toolkit to guide best 
practice with antineoplastic drug administration and proper waste disposal methods. 
The key stakeholders of the proposed DNP project include staff in the AIC where the 
project will take place, the Assistant Unit Manager (AUM), the Cancer Center Executive 
Director, the Director of Cancer Services, the Cancer Committee, and the “Environment of Care” 
Workstream Committee. Also, the USP <800> Committee will be interested in the outcome of 
the DNP project because the results may be applicable to other hospital-based AICs within the 
healthcare system. The Cancer Committee has chosen this project as one of its’ Quality 
Improvement (QI) initiatives for 2020. Each year the Cancer Committee must report QI results 
directly to the Commission on Cancer (COC) Programs to maintain accreditation. This project 
meets Program Standard 4.8 (Quality Improvements, see Appendix B). Finally, the USP <800> 
Standards are not optional, and the Cancer Center must comply with all applicable standards. 
Proposed Intervention 
The purpose of implementing an HD safe-handling PPE toolkit is intended to gain better 
PPE adherence from infusion nurses in the AIC and to create an environment where a culture of 
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safety can exist. The DNP project will be conducted in an AIC adjacent to a large tertiary 
medical center campus. The AIC consists of the following healthcare personnel: 15 registered 
nurses, two patient care associates (previously called nurses’ aides), one Assistant Unit Manager 
(AUM), one unit secretary, and five oncology nurse practitioners (NPs). Nurses generally work 
10-hour shifts from 8:00 a.m. to 6:30 p.m. The AIC is open seven days per week. The AUM 
reports directly to the Director of Cancer Services weekly, the Executive Director of Cancer 
Center monthly, and to the Cancer Committee at least quarterly. 
The Cancer Committee provides program oversight and also ensures compliance with all 
rules and regulations set forth by federal, state, and local authorities. The Committee is also 
responsible for engaging in QI projects centered on quality patient outcomes and patient safety to 
meet the COC standards for Cancer Centers (see Appendix B). This committee is aware of QI 
methodology and familiar with the elements of Donabedian’s conceptual framework of structure, 
process, and outcome. However, the COC has outlined specific steps for project compliance, 
which includes creating an independent QI committee to oversee all cancer center projects. A 
description of the COC’s project steps is described in a Basic Steps of Standard Compliance 
Flow Sheet (see Appendix C). I will work directly with the QI Committee on this project. 
The interventions will be implemented over five months, from September 2019 through 
February 1, 2020. Once the project is completed, and evidence of improvement in nurse 
adherence with PPE use and compliance with hospital policies and USP <800> standards are 
achieved, the plan is to analyze and report the interventions’ results to other executive leadership 
in the health system. To ensure Internal Review Board (IRB) approval is not required for the 
implementation of the project, I will submit a DNP Statement of Non-Research Determination 
form to my DNP Committee (see Appendix D), as well as provide a request for review to the 
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healthcare system’s IRB to confirm this is a QI project. The interventions will consist of: (a) the 
development of an HD safe-handling PPE toolkit, (b) PPE observation tool, (c) observations of 
chemotherapy safe-handling adherence, (d) expert panel discussion, (e) nursing skills session, (f) 
safe-handling adherence between observation and self-assessment survey, (g) hazardous drug 
administration safe handling peer-to-peer checklist, and (h) the use of a performance dashboard. 
Each of these interventions will be described in detail. 
Hazardous drug safe-handling PPE toolkit. The toolkit will contain available evidence 
as described in the literature, align with the policy manual, and become a practical guide for 
frontline infusion clinicians. The toolkit will be divided into three sections: Part A (Portfolio of 
the Evidence), Part B (How to Implement Interventions), and Part C (Resource Tools). Part A 
will contain current EBP research and methods (evidence table) and hospital and AIC policies 
for safe HD administration. Part B will include a PowerPoint training module for HD PPE 
selection. Part C will contain useful tools, such as the confidential Pre-Observation tool, 
hazardous drug administration safe handling checklist for peer-to-peer feedback, and 
observations of chemotherapy safe-handling adherence tool. Furthermore, a list of common HDs 
provided by the ambulatory care pharmacy will be added for reference and include exposure risk 
levels and specific PPE requirements for  potential low-, moderate-, and high-risk situations. 
Confidential pre-observation assessment. Confidential observations of staff nurses’ 
handling, administering, and discarding chemotherapy waste will be done by the DNP student, a 
clinical nurse educator, two oncology registered NPs, and one infusion pharmacist to determine 
the baseline level of adherence using an established PPE observation tool (Hennessey & Dynan, 
2014). I will collect and analyze results to determine the current adherence rate of PPE use 
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before the intervention based upon recommendations from the Cancer Committee and 
“Environment of Care” Workstream Committee groups. 
Expert panel discussion. An educational session introducing the USP <800> Standards 
related to PPE use will be provided by a panel of oncology certified nurses, an occupational 
health nurse, a clinical nurse leader, medical oncologist, and pharmacist to increase awareness of 
personal risks associated with HD exposure and to address potential and actual barriers that 
hinder compliance in the current practice environment. 
Nurse skills session. The AIC nurses will attend a 2-hour skills session to introduce them 
to the concepts of the USP <800> Standards within the department. Orem’s self-care deficit 
theory will be used to teach how the theory applies to personal safety and nursing practice. The 
nurses will also receive feedback on the current state of safe-handling methods in the unit and 
how the focus of the DNP project includes improving the workplace environment to promote a 
culture of safety. A PPE demonstration and practice session will be provided, and a peer-to-peer 
tip sheet and the toolkit will be introduced. 
Safe-handling adherence between observation and self-assessment. A Qualtrics 
survey will be sent via email to infusion nurses to obtain self-assessments of adherence to PPE 
and compliance with organizational policies. Results will be compared to actual observations in 
the AIC by trained staff. 
Hazardous Drug Administration Safe Handling Checklist (Peer-to-Peer Tool). The 
organization has obtained permission from the authors to utilize this tool created by two nurse 
researchers, Martha Polovich and Mikaela Olsen. The tool will be useful in providing 
instructions and feedback on several different HD administration techniques such as IV 
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infusions, IV push medications, intramuscular and subcutaneous injections, and oral drugs, 
including liquid preparations (Polovich & Olsen, 2017, p.96-97). 
Performance dashboard. A visual display to create transparency and ownership will be 
posted on the huddle board identifying critical elements of the intervention phases. Metrics will 
be discussed in daily huddles to encourage participation, brief staff on the current status of the 
project, and to develop the concept of an environmental safety culture (OSC). 
Gap analysis. Better education is needed to ensure that employers and HCWs are fully 
aware of the risks and potential adverse health consequences of exposure to these toxic drugs 
(Boiano et al., 2014). For example, nurses who work in high exposure environments understand 
the inherent risks, yet compliance may be ignored, as evidenced by the lack of PPE use.  
Additional gaps specific to the AIC include scheduling demands and workload pressures placed 
on pharmacists and nurses. Research shows that the average patients per day significantly 
influence total HD precautions. It is safe to say that HD precautions occur with fewer patients 
per nurse, yet patient acuity levels may change dramatically throughout the day, jeopardizing 
real-time safety. The gap analysis outlines common issues concerning PPE use and the 
organizations’ conflicting agenda (see Appendix E). 
Infusion managers may benefit from a unit-specific acuity scheduling template and a 
toolkit outlining the risk levels of exposure to staff, including facilitating clinician input on the 
decision to lower workloads and eliminate structural barriers to safe handling (Mendelsohn-
Victor, McCullagh, & Friese, 2017). Hospital, pharmacy, and unit-specific interventions could 
contribute to a more reliable work environment balance. Safe-handling practices, such as PPE 
worn by nurses, reduce exposure risks, and the likelihood of adverse health effects from 
antineoplastic drug residues (NIOSH, 2016). However, not all exposure risks involve nursing 
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practice, as each step in the handling process, should be managed appropriately. Evidence-based 
practice, policies and procedures, engineering controls, unit-based workplace designs, and the 
HCWs commitment to improving safety must guide processes and outcomes (Callahan et al., 
2016). 
Gantt chart. The project will be divided into four implementation phases, as outlined in 
the Gantt chart (see Appendix F). The first phase will commence in September 2019. 
Confidential observations of the AIC infusion nurses’ handling, administering, and discarding 
chemotherapy will be completed by the DNP student, a clinical nurse educator, two oncology 
NPs, and one infusion pharmacist to determine the baseline level of adherence with safe handling 
using the established PPE observation tool by Hennessey and Dynan (2014). The second phase 
will take place in October 2019, where an expert panel discussion will be held for all staff in the 
AIC. The panel will consist of oncology certified nurses, one occupational health nurse, a 
clinical nurse leader, infusion pharmacist, and medical oncologist. Nurses will also be provided 
access to an online survey to perform a self-assessment of safe-handling adherence. Beginning 
phase three in November 2019, individual nurse audits will be performed to assess compliance 
with PPE use, and immediate peer-to-peer feedback will be provided to encourage best practice. 
Phase four will commence on December 1, 2019. Nurses’ adherence will be expected to comply 
with the USP <800> regulations and current hospital policies and procedures for PPE use with 
all HD handling.  
Work breakdown structure. The purpose of the work breakdown structure (WBS) is to 
have a plan and infrastructure, supporting documentation and metrics tools, comprehensive 
education strategies, and a monitoring plan to maintain fiscal responsibility and increase chances 
of sustainability (see Appendices G, H, and I). Since the hospital has been proactively preparing 
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for hospital and pharmacy compliance, this project will serve as an adjunct to other 
administration processes requiring PPE use and ensure that the cancer center is provided with the 
resources necessary for USP <800> readiness. 
There are five phases of development in the WBS: (1) initiation, (2) planning, (3) 
execution, (4) control, and (5) closeout. During the initiation phase, the project manager will 
attend the organization’s USP <800> committee meeting to share information about the 
proposed project plan and gather recommendations from the group. The USP <800> 
environment of care committee will sign and approve a charter. The PPE workgroup will 
develop a preliminary scope statement and solidify team member participation during the 
planning phase. The DNP student will develop the final project plan, with the cancer committee 
accepting for final approval.  
The execution phase includes a kickoff meeting, verifying and validating the USP <800> 
PPE requirements, introducing the toolkit, deciding on the quantity of PPE per unit, testing in the 
AIC, and completing the PPE toolkit. Staff training and Go Live date will be determined. The 
control phase of the WBS includes project management, project status meetings, risk 
management, and updating the project management plan. Finally, the closeout phase is one of the 
essential aspects of the project. An audit procurement and lessons learned session is instrumental 
because all of the completed steps will be analyzed and reported to various committees involved. 
All files and records will be collected and archived. Formal acceptance of the toolkit as an 
important resource for AIC nurses will be realized. 
Responsibility/Communication plan. The proposed QI intervention is part of an 
organizational work stream committee that exists to address the environment of care readiness 
plan related to USP <800>. The initiative is also of interest to the cancer committee because it 
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satisfies a mandatory requirement issued by the COC practice (see Appendix J). The cancer 
committee will make an overall recommendation to the work stream committee to develop, 
implement, and report on the USP <800> Standards for the entire cancer center. However, a 
smaller workgroup committee will focus on the AIC project where HCW exposure risks are the 
highest. Project charter team members will meet weekly to discuss the next steps and progress 
toward agreed upon goals. 
A separate PPE workgroup will oversee the selection of protective equipment and 
measures while assessing the financial impact on the AIC and organization. Many healthcare 
personnel will assist with gathering content to be used in the toolkit. Training and monitoring of 
nurses will be a combined effort by the AUM, clinical nurse educator, and others. The DNP 
student will work cohesively with each of the groups throughout the process to ensure timely 
coordination and communication, thereby providing efficient use of available resources and time. 
SWOT analysis of the current state. The SWOT analysis (strengths, weaknesses, 
opportunities, and threats) is a useful tool for identifying many factors that may impact the 
success of the project (see Appendix K). The following summary of the findings is discussed 
below. 
Strengths. A system-wide approach in how the organization will address the new 
standards is now in process. Executive leadership and frontline managers are working to identify 
gaps with HD handling that include transporting, receiving, storing, preparing, administering, 
and disposing of HD waste. Supplies necessary for safe handling are under review. Standards of 
practice are being aligned across the healthcare system to improve communication and 
understanding among physicians, pharmacists, nurses, and many others involved in these critical 
steps. 
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Weaknesses. The most significant flaw is the nurses’ resistance to wearing PPE with HD 
administration in the AIC. Even after focused training sessions and reminders in the past, nurses 
remain complacent (Friese et al., 2019). Without addressing negative attitudes and beliefs toward 
PPE use, improving personal safety will remain unsustainable. Nurses must understand that 
personal safety will be jeopardized, and diligent PPE adherence will prevent potential short- and 
long-term adverse health effects. Policies and procedures for HD handling are contradictory in 
some settings and merely indicate PPE use as a guideline. However, a renewed focus on USP 
<800> creates the urgency to reevaluate processes and include the mandatory requirements based 
on exposure risk factors. Also, increased costs associated with purchasing PPE, waste 
management, and decontamination wipes are unpredictable. 
Opportunities. Opportunities to comply with USP <800> specific to PPE use are making 
national news and bringing awareness to the public about the risks of HD residue exposure in 
their communities. Local leaders and waste management services are reviewing external pressure 
from communities to control environmental HD waste. Increasing demand for patient education 
provides opportunities for nurses to engage the public on safe-handling awareness, not only in 
controlled healthcare settings but also inside their own homes. 
Threats. Threats to meet upcoming USP <800> Standards for PPE use may be associated 
with the high cost of equipment, regular and random monitoring of the HCW and AIC 
environment, inability to maintain and recruit qualified nurses experienced with HD practices, 
and a lack of focus on ambulatory care practices during program development. Also, there may 
be a loss of funding in the coming years for healthcare programs that strive to meet the demands 
of the 21st Century Cures Act. This legislation will increase Medicare infusion access to eligible 
patients and impose significant financial disincentives to pharmacy services. It is vital that PPE 
USP <800> AND THE PPE PROJECT 24 
and waste management strategies remain part of this new legislation to prevent the dumping of 
chemical waste into communities and to ensure accessibility to appropriate PPE. 
Proposed Budget 
The AIC is the highest user of PPE in the patient care setting within the organization for 
HD handling. With 2,800 patient visits projected per month in 2020, the costs of providing PPE 
to HCWs is daunting. The annual cost alone accounts for an increase in the budget of over 20% 
in 2020. Purchasing departments generally choose contracted vendors to get better pricing; 
however, various committees are reviewing several other non-contracted vendors to improve 
pricing options. Nursing is evaluating different PPE products for comfort and ease of use with 
hopes to improve adherence and compliance. 
Nonmonetary benefits include ethical, moral, and harm reduction efforts to protect staff 
and patients that cannot be quantified into a dollar amount. Interestingly, efforts are underway to 
create a national registry where health care workers can report HD exposures that include 
chemotherapy and report adverse side effects experienced such as headache, dizziness, nausea, 
hair loss, miscarriage, and fertility problems (Friese, et al., 2019).  A toolkit will become a quick 
and useful staff resource to guide best practice. The budget estimates document (see Appendix 
L) is a rough draft depicting financial considerations for implementing the project. Future 
dissemination of the toolkit is excluded. Projections include staff education, a learning module, 
expert panel discussion, pre- and post-observations of PPE use, and peer-to-peer feedback tip 
sheet tool. 
Proposed Outcome Measures 
The PPE observation tool will be used to collect pre-intervention data to evaluate the 
current state of adherence to PPE use with HD administration. To assess observations of 
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handling, administering, and disposing of chemotherapy, a 15-item yes or no nurse skill checklist 
will be used. To retrieve self-assessments of nurses’ adherence to PPE use and to follow 
organizational HD policies, a 9-item questionnaire using a 5-point Likert scale response set, 
ranging from 0 (never) to 4 (always) plus a not applicable option, will be given. The content for 
this tool is derived from NIOSH, ONS guidelines, USP <800> Standards, and the healthcare 
organization’s updated policies for HD safe handling. Also collected and analyzed will be nurse 
demographics and professional characteristics through self-assessment survey questions using 
checkbox and fill-in-the-blank responses. 
Proposed Analysis 
Data analysis will involve describing the nurse skills checklist frequencies and self-
assessment of RN characteristics using medians and quartiles of counts and percentages for all 
categorical variables. Mean scores for the 9-item self-assessment questionnaire on PPE 
recommendations will be calculated by averaging responses across administration, 
disconnection, and disposal of chemotherapy. After matching factors for the nurse skill checklist 
and self-assessment questionnaire, data will be compared to learn if differences exist in 
adherence to PPE recommendations and hospital policies for safe chemotherapy handling. All 
analyses will be two-tailed and will be analyzed at a significance level of 0.05, SAS Version 24.   
Ethical Considerations 
One of the core Jesuit values is forming and educating agents of change, which means 
teaching behaviors that reflect critical thought and responsible action on moral and ethical issues. 
Infusion nurses must change attitudes and behaviors on using PPE because of the high-risk 
nature of harm due to HD contamination. It is morally and ethically irresponsible to subject 
patients and families to harmful HD residues because of personal convictions. The American 
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Nurses Association (ANA, 2015) ethical standard that relates to this evidence-based project is 
Provision 3, “The nurse promotes, advocates for, and protects the rights, health, and safety of the 
patient” (p. 9).   
Provision 3.4 states that nurses have a professional responsibility to promote a culture of 
safety. This provision extends beyond reporting events and errors that occur to patients and 
includes “adherence to policies that promote patient health and safety” (ANA, 2015, p. 12). This 
QI project hopes to empower nurses to behave more responsibly to protect patients from HD 
exposure while in their care. Also, nurses will educate other staff and the public by role-
modeling proper PPE use with HD handling.  Efforts will be made to minimize the psychological 
stress patients, and caregivers may feel while observing the PPE intervention by informing them 
of the new regulations to improve patient and nurse safety with HD administration.  Nurses are 
encouraged to incorporate HD education into their teaching plan via verbal and written 
communication methods and emphasize how to prevent home environmental contamination.  
Since the focus of this project was on QI, it does not require an IRB approval for 
implementation, per the University of San Francisco’s IRB. The project was evaluated and 
approved as a QI project through the University of San Francisco School of Nursing and Health 
Professionals. However, the healthcare organization requires IRB evaluation, so the DNP project 
will be referred to the committee for comments and approval. 
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Section IV: Discussion 
Limitations 
The hospital has organized multiple interdisciplinary teams to develop a comprehensive 
program to comply with the USP <800> Standards, yet infusion nurses in the cancer center have 
not been involved and are unfamiliar with the new mandatory safe-handling requirements. A 
representative from the Cancer Center will be included in future discussions and planning 
phases. Personal protective equipment and supplies, such as gloves, gowns, facemasks, eye 
protection, and respiratory devices, should be tested by nurses for comfort and ease of use. 
Comfort, choice, and ease of use may be secondary to organizations who must control expenses. 
Current budgets for the Cancer Center and AIC are under review, and additional funds will be 
requested to ensure sufficient PPE is allotted to the AIC.  
Another limitation is that the DNP project will be conducted in a single center, and even 
though response rates for the self-assessment survey include the total AIC nursing population, 
the overall sample size may be too small compared to larger AICs. A multi-center approach 
would increase the value of the findings related to PPE adherence in AICs. In addition, it is 
possible the nurses could be evaluated multiple times on different days by different observers. 
The registered nurses who complete the self-assessments may be different from the ones who are 
being observed each day. 
Furthermore, environmental wipe sampling and staff health monitoring will be costly, yet 
vitally important for all working in high exposure risk areas. The organization is self-insured for 
workers compensation and has increased efforts to proactively address additional costs due to 
employee adverse health events following exposure incidents through staff medical monitoring, 
HD education and training.  Funding for the project should be added to the 2020 budget 
beginning in July 2019 to make additional preparations for USP <800> compliance by December 
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1, 2019. However, budget considerations in the Spring of 2019 require an additional 20% 
increase to cover expenses for PPE, waste disposal bins, sharps disposal devices, increased waste 
disposal services, and HD environmental monitoring supplies until the new budget has been 
approved. 
Conclusions 
Maintaining supportive best practices with HD administration and PPE provides a 
message of commitment to staff and the public that safety concerns are paramount. Similar to 
interventions for handwashing to prevent contamination, patients should be encouraged to speak 
up when they view a situation where PPE should be utilized. Critical components of sustained 
success are staff education and ownership of the required changes relevant to PPE use, peer-
performance monitoring, leadership support, prioritization of workload, and continuous 
monitoring and feedback regarding performance. The fact that all involved in patient care have a 
responsibility to maintain the standard is well-established and accepted. Current data are limited 
on the long-term effects of HD exposure; yet, the literature concludes that there is no well-
defined safe level of exposure. Control systems, similar to individual staff radiation exposure 
tags that monitor monthly levels in the field of radiology, are currently unavailable. Enforceable 
regulations to protect workers must be monitored by state, federal, and accreditation 
organizations to increase compliance and to sustain pressure on healthcare providers to 
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Appendix A: Evidence Table  
 
Citation  Statistical Tools Data Collected Quality of Evidence  Highlights from Article 
Bohlandt et al. 
(2017) 
Wipe samples/surface 
monitoring, urine collection, 
questionnaire on household.  
Analyses carried out under 
strict internal and external 
quality assurances; 
SPSS Version 21; 
Spearman rank correlation 
test/Mann-Whitney-U test for 
independent variables. 
 
Setting: Patient homes s/p 
chemo admin 
Sample: 
1) 265 wipe samples/13 
homes at two times after 
chemo from common 
household surfaces.  
2) 62 urine samples from 
patients and family members 
on three days.  
3) Drugs analyzed: 
cyclophosphamide (CP), 5-
fluorouracil (5-FU), and 
platinum (PT). 
Time Frame: Up to 4 days 
Results: Substantial 
contamination on every 
surface type (PT: 0.02-42.5 
pg/cm2; 5-FU: ND 






Spot samples, both wipe and 
urine samples, only reflect the 
current situation and that 
probably different results may 
have been found when 
performing continuous urine 
collection.  
Aim: To evaluate the surface 
contamination and the 
potential uptake of 
antineoplastic drug residues 
by family members at home 
of chemotherapy patients. 
 
Exposure was evident in 
patient homes on various 
surfaces. Adequate hygienic 
and protective measures are 
necessary to minimize the 
exposure risk for cohabitants. 
 
Elevated levels in patient’s 
urine more than 48 hours, no 
drug residues in family 
members’ urine. 
Boiano et al. 
(2014)  
 
NIOSH Survey of Healthcare 
Workers (an anonymous, 
multi-module, web-based 
survey), SAS 9.3 to analyze 
data. 
Setting: NIOSH web-based 
survey 
Sample: 98% of 2,069 
respondents were nurses 
Time Frame: Jan 28 to Mar 
29, 2011 
Results: The survey results 
show deficiencies related to 
the lack/infrequency of 





Survey was targeted to 
members of professional 
practice organizations and are 
not generalizable to all 
healthcare workers or to all 
members of each of the 
Authoritative guidelines are 
not being universally 
followed. 
 
Activities that increased 
exposure risk per 
respondents, included: failure 
to wear nonabsorbent gown 
with closed front and tight 
cuffs (42%), IV tubing 
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employer procedures, and 
awareness of national safe-
handling guidelines. 
Multiple breaches in safe 
work practices (CSTDs, luer-




The survey was only 
available to members with 
email addresses and internet 
access. 
 
primed with antineoplastic 
drug (6%) or by pharmacy 
(12%), potentially 
contaminated clothing taken 
home (12%), gloves (12%), 
lack of hazard awareness 
training (4%). 
 
Most common reason for not 
wearing gloves or gowns was 
“skin exposure was minimal,” 
but respondents reported skin 
contact during handling and 
administration. 





correlational design study. 
Survey Hazardous Drug 
Handling Questionnaire. 
Data were analyzed using 
descriptive statistics and 
multiple regression analysis. 
(main research variables: 
exposure knowledge, self-
efficacy, perceived risk, 
interpersonal influences, and 
workplace safety climate). 
Survey Monkey software 
database, SPSS V21.0, 
Spearman’s correlation 
coefficients, 
Wilcoxon rank sum tests.  
Setting: The National 
Institutes of Health Clinical 
Center in Bethesda, Maryland 
Sample: 196 eligible/115 RNs 
working on high-volume HD 
administration units. 
Time Frame:   
Results: Total mean HD 
precaution use proved highest 
during HD administration and 
lowest for handling excreta at 
48 hours. Average patients 
per day significantly 
influenced total HD 
precaution: more precaution 






Self-report survey conducted 
in one specialized research 
hospital and cannot be 
generalized without 
replication to other settings. 
Nurses were required to 
attend formal training to 
administer chemo and 
biotherapy and gain oncology 
nursing certification 
Purpose: To identify factors 
associated with oncology 
nurses’ use of HD safe-
handling precautions in 
inpatient clinical research 
units. 
 
Data were analyzed using 
descriptive statistics and 
multiple regression analysis. 
(main research variables: 
exposure knowledge, self-
efficacy, perceived risk, 
interpersonal influences, and 
workplace safety climate). 
Conclusions: Despite high 
exposure knowledge, barriers 
to PPE use and conflict of 
interest may contribute to 
reduced adoption of personal 
protective practices among 
oncology nurses. 
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Hospitals and unit-specific 
factors captured by the 
predictor variables could 
contribute to institutional HD 
policy. 




study to compare objective 
and subjective nurse 
behavior, micro-ethnography 
and questionnaires. 
Setting: Cleveland Clinic 
Sample: 22 cases of chemo 
handling observed, 12 of 33 
nurses completed 
questionnaires. 
Time Frame: Jan 2012 to Mar 
2013 
Results: Data analysis 
involved describing the nurse 
skill checklist frequencies and 
self-assessment of RN 
characteristics using medians 
and quartiles of counts and 







Study conducted in a single 
center, and the sample size 
was small. 
Sample size for nurse 
observations was small. 
Lack of uniformity in 
assessment item working 
could have led to differences 
in reported frequencies in 
adherence to PPE 
recommendations. One nurse 
may have been observed 
more than once on different 
days. Nurses observed had 
two or more years nursing 
experience in oncology 
nursing and may not have 
been well matched in the 
group comparisons. 
Analyses were based on 
group findings; no 
correlations were noted 
between observed behaviors 
and self-assessment by 
individual nurses. 
The aims of the pilot study 
were to examine actual and 
subjective ambulatory 
oncology nurse adherence to 
chemotherapy safe-handling 
with NIOSH PPE and 
hospital policy exposure 
controls. 
 
Consistent adherence to 
practice expectations may 
require more than an annual 
competency assessment. 
 
Chemotherapy exposure is a 
team concern in that one 
healthcare clinician can 
follow all policies, yet still be 
exposed to chemo if others 
fail to do so. 
Connor et al. 
(2014) 
Literature search using the 
following databases: 
Setting: Literature review Level: III 
Quality: A 
Antineoplastic drugs are 
highly toxic in patients 
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 • Canadian 
• CINAHL 
• CISILO 
• DTIC, Embase 





• PubMed, Risk 
abstracts 
• Toxicology Abstracts 











Sample: 18 peer-reviewed, 
English language publications 
of occupational exposure and 
reproductive outcomes 
studies. 
Time Frame: Literature 
review completed 1980 to 
February 2014 
Results: While effect sizes 
varied with study size and 
population, occupational 
exposure to antineoplastic 
drugs appear to raise the risk 
of both congenital 
malformations and 
miscarriage. Studies of 
infertility and time-to-
pregnancy also suggested risk 
for sub-fertility. 
Measurement of surface 
contamination is the best 
indicator of the level of 
environmental contamination 
in areas where Ads are 
prepared, administered to 
patients, or otherwise handled 
(such as receiving areas, 
transit routes throughout the 
facility, and waste storage 
areas). 
The odds ratio of adjusted 
models ranged from 1.36 
(95% CI, 0.59-3.14) to 5.1 
(95% CI, 1.1 -23.6) 
 
Limitations: 
Small sample sizes 
5/8 studies had 10 or fewer 
exposed cases. All studies 
had fewer than 20 exposed 
cases. Limited ability to 
adjust for confounding; the 
need to group anomalies that 
had different etiologies and 
wide confidence intervals, 
which reflect poor statistical 
power.  
receiving treatment and 
adverse reproductive effects 
have been well documented 
in these patients. HCW with 
chronic, low-level 
occupational exposure to 
these drugs also appear to 
have an increased risk of 
adverse reproductive 
outcomes. Additional 
precautions to prevent 
exposure should be 
considered (NIOSH). 
Some studies have shown an 
association between surface 
contamination and worker 
exposure. 
For pregnant women, the 
window of risk begins one 
month before conception and 
lasts through pregnancy (most 
vulnerable in first trimester). 
Breast milk is affected by HD 
exposure. 
A man’s sperm is vulnerable 
to HDs from as early as 2 
months before conception. 
Connor et al. 
(2016)  
Not stated Setting: Article review by 
experts at NIOSH 
Level:  III 
Quality: A 
The purpose of the article was 
to review published studies of 
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 Sample: not stated 
Time Frame: not stated 
Results: 
A comprehensive safe-
handling program for ADs 
may utilize wipe sampling as 
a screening tool to evaluate 
the environmental 
contamination and strive to 
reduce contamination levels, 
as much as possible, using the 
industrial hygiene hierarchy 
of controls. 
 
Wipe sample area 
recommendations: 
Nurses’ station storage area 
for IV bags 
Countertops 
Furniture in patient rooms 
Infusion pump 
Door handles, door knobs, 
other high-touch areas 
Computer keyboard/mouse 
Floor in patient room 
Floor in restroom 
wipe sampling for 
antineoplastic and other HDs, 
to summarize the methods in 
use by various organizations 
and researchers, and to 
provide some basic guidance 
for conducting surface wipe 









• Cochrane Library 
• EMBASE 
English language 
Setting: Systematic literature 
review 
Sample: 29 publications met 
final review criteria 
Time Frame: 1979 to 2014 
Results: 5 major strategies 
identified (engineering 
controls, PPE, medical and 
environmental monitoring, 
hazard identification, need for 
comprehensive HD control 
program that includes 
education and training for 
HCWs). 
Transparency in every step in 
the chain of custody is 
needed. Clear signs or labels, 
including electronic 
identifiers, and clear 
instructions that prompt what 
to do next are needed. 
Level: III 
Quality: A 
The systematic review was 
conducted to identify 
evidence-based strategies for 
protecting all HCWs, from 
those involved in handling 
packaged HDs to those who 
dispose of body fluids of 
individuals taking these 
medications. 
One problem with wipe 
testing is that there is no 
minimum acceptable 
exposure level for 
chemotherapy or other HDs.  
Testing workers’ urine/blood 
samples may be difficult to 
operationalize across large 
healthcare systems. Financial 
and ethical implications must 
be considered, specifically 
with how to counsel staff 
members with positive results 
of urine or blood samples. 
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Barriers such as 
understaffing, the physical 
layout of a unit, and time 
constraints can negatively 
impact adherence. 
DeJoy et al. 
(2017)   
Data came from the 2011 
NIOSH Health and Safety 
Practices Survey of 




Statistical analyses were 
performed using SAS 9.4 
software in three stages: (1) 
descriptive analyses, (2) 
factor analysis of safety 
perception, and (3) 
psychometric analyses. 
Setting: Online survey 
Sample: Nurses (N=1,814) 
who had administered IV 
HDs in the 7 calendar days 
prior to the survey and whose 
employer was either a 
hospital or ambulatory 
healthcare center. 
Time frame: Survey was 
available for 8 weeks.  
Results: The study showed 
lower likelihoods of exposure 
when staffing and resources 
were adequate and when 
orders and doses were 






• Cross-sectional study limits 
the ability to make causal 
interpretations. 
• Survey respondents were 
solicited from membership 
rolls of professional 
organizations and may not 
represent all nurses who 
administer HDs. 
• The sample was limited to 
nurses working in the U.S. 
• Data collected were 
analyzed at the individual 
level. 







examine predictors of the use 
of PPE and engineering 
controls and adverse events 
involving IV HDs in a 
relatively large and diverse 
sample of nurses.  
The study examined the 
effects of pertinent 
organization safety practices 
and perceived safety climate 
on the use of PPE, 
engineering controls, and 
adverse events (spill/leak or 
skin contact) involving liquid 
antineoplastic drugs. 
14% of nurses reported an 
adverse event. 
 
Results point to the value of 
implementing a 
comprehensive health and 
safety program that uses 
available hazard controls and 
effectively communicates and 
demonstrates the importance 
of safe-handling practices. 
Such actions also contribute 
to creating a positive safety 
climate. 
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Having an adequate 





PPE use was lower among 
nurses working in ambulatory 
infusion centers and be 
caused by less formalized 
safety programs and perhaps 
less direct supervision of 
those administering HDs. 
Both of these factors could 
lead to diminished adherence. 
Friese et al. 




Methods & variables:  
1. Revised Drug Handling 
Questionnaire (Martin & 
Larson, 2003; Polovich & 
Clark, 2012) 
2. Practice Environment Scale 
(Friese, 2012). 
3. Safety Organizing Scale 
(Vogus & Sutcliffe, 2006) 
4. The authors measured 
knowledge of HD handling 
using a team-generated, pilot-
tested, 10-item questionnaire. 
5. Occupational Dermal 
Survey to measure perceived 
risk (Geer, Curbow, Anna, 
Lees, & Buckley, 2006). 
 
In a cluster randomized 
controlled trial, 136 nurses in 
Setting: 12 ambulatory 
oncology settings in the 
United States. 15 sites were 
eligible, but 3 declined 
participating in study 
12 sites were randomized 
6 sites control arm 
6 sites allocated to 
intervention. 
 
Sample: 396 nurses, 257 of 
who completed baseline and 
primary endpoint surveys. 
 
Time frame: March 2015 to 
March 2017 
Results: Control and 
intervention sites had 
suboptimal PPE use before 





First, the study took place in a 
convenience sample of 
academic health centers with 
high-volume cancer 
programs. (Results may not 
generalize to smaller or 
community-based oncology 
settings). 
Second, the calculated 
reliability of the outcome 
measure in the current sample 
was relatively low (0.46 for 
the 3-item measure and 0.5 
for the 5-item measure 
considered in the sensitivity 
analysis). 
Purpose/Objectives: To 
evaluate whether a web-based 
intervention improved PPE 
use among oncology nurses 
who handle hazardous drugs. 
 
Findings: It is clear that 
education and engagement of 
nursing personnel is not 
sufficient to improve PPE use 
– systematic approaches may 
result in improved practice. 
  
Conclusion: Despite four 
decades of research, current 
use of PPE remains 
suboptimal in ambulatory 
oncology settings. A theory-
informed, web-based 
educational intervention to 
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control settings received a 
one-hour educational module 
on PPE use with quarterly 
reminders, and 121 nurses in 
treatment settings received 
the control intervention plus 
tailored messages to address 
perceived barriers and 
quarterly data gathered in HD 
spills across all study settings. 
The primary outcome was 
nurse-reported PPE use. 
 
The primary outcome was 
PPE use, as measured by the 
previously published Revised 
Drug Handling Questionnaire 
(Martin & Larson, 2003; 
Polovich & Clark, 2012). 
significant differences were 
observed in PPE-use 
knowledge or perceived 
barriers. Participants reported 
high satisfaction with the 
study experience. 
 
RNs failed to improve PPE 
use in the ambulatory 
oncology setting. 
A multi-faceted strategy 
(equipment changes, 
standardized policies, 
educational efforts, and 
leadership support) across 
multiple levels (units, 
hospitals, and health systems, 
and professional 
organizations) may be 
required to improve 
adherence to HD-handling 
guidance. 
 
Implications for Nursing:  
HD exposure confers notable 
health risks to healthcare 
workers. To improve HD 
handling, occupational 
healthcare workers, health 
systems, and professional 
organizations should consider 
coordinated efforts to 
implement policy and 
practice changes. 
 
Other Data of Interest: 
Future research efforts would 
benefit from development and 
testing of novel measures of 
PPE use and evaluation of 
optimal measurement times 
after delivering educational 
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interventions and delivering 
study reminders. 
 
He et al. (2017)    
 
1.Cross-sectional, multi-state 
mailed survey to ONS 
members (N=654) 
Tool: Revised Hazardous 
Drug Handling Questionnaire 
(Martin & Larson, 2003; 
Polovich & Clark, 2012) 
2. Bivariate and multivariable 
regression analyses 
3. Covariates: nursing 
workloads, nurses’ practice 
environments, and barriers to 
PPE use 
4. Dillman’s total design 
method to maximize response 
rates (personalized cover 
letters, $40 cash incentives, 
three monthly reminders to 
non-responders) 
5. Safety Organizing Scale to 
measure collective behaviors 
performed by employees in 
high-reliability organizations 
Setting: Ambulatory 
oncology practices in CA, 
GA, and MI 
Sample: 252 ONS members 
who administer hazardous 
drugs 
Time frame: February to 
September 2014 
Results:  
437 nurses completed surveys 
(67% response). Final 
analytical sample (n=252), 
97% women, 79% 43 years or 
older, 75% with at least 6 
years of nursing experience, 
and 96% worked in outpatient 
oncology settings. The 
sample mean for the PPE-use 
score was 2.4 (SD=1) out of a 








The internal reliability of the 
dependent variable – the PPE-
use scale – was lower in the 
current sample (0.61) than 
previously reported (Geer et 
al., 2006).   
The distribution of various 
PPE (included on the PPE-
use scale) had a bimodal 
pattern; many respondents 
reported either using PPE 
very frequently or never. 
Other limitations included a 
varying number of 
respondents per practice (1-
12 nurses) and missing data.   
Roughly a third of practices 
had only one nurse informant. 
These limitations are 
somewhat offset by the large 
sample size, high response, 
rate, and geographic 
diversity. 
Purpose/Objectives: To 
examine patterns and 
organizational correlates of 
PPE use and hazardous drug 
spills. 
 
Findings: 26% reported 
recent drug spill, 90% wore 
only 1 pair of chemotherapy-
tested gloves. PPE use was 
associated with increased 
nurse participation in practice 
affairs, non-private 
ownership, increased nursing 
workloads, and fewer barriers 
to PPE use. Spills were 
associated with significantly 
less favorable manager 
leadership and support and 
higher workloads. 
 
Conclusion: Drug spills occur 
in ambulatory settings. PPE 
use remains low, and barriers 
to PPE use persist. Higher 
workloads are associated with 
more drug spills. As nursing 
workloads increased by one 
patient, the odds of HD spills 
increased by 3% (OR=1.03, 
95% CI [1.01-1.06], p=0.01). 
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Implications for Nursing: 
Managers should monitor and 
correct aberrant workloads 
and ensure that PPE is 
available and that staff are 
trained. 
 
Other Data of Interest: 
The study findings 
underscore the need to 
improve individual adherence 
through modifiable 
administrative controls (e.g., 
commitments to safety 
culture, improved nurse 
practice environments, 
thoughtful attention to nurse 




Dynan (2014)  
Framework for the Model for 
Improvement (Langley, 
Moen, Nolan, Norman, & 
Provost, 1996), a continuous 
process of tests of change, 
performance measurement, 
and feedback was put into 
place to improve 
performance. 
Monthly audits with PPE 
Observation Tool created by 
Dana Farber educators. 
Setting: Dana Farber Cancer 
Institute 
Sample: Infusion nurses in 
ambulatory care 
Time Frame: 2009-2014 
Results: Previous compliance 
rates 30%-40%  
Key components of the 
sustained success of this 
initiative are staff education 
and ownership of the required 
changes, peer-performance 
monitoring, leadership 
support and prioritization of 
the work, staff involvement in 





A program was developed 
that incorporated not only 
monitoring and reporting 
compliance of the use of PPE, 
but also engaged the staff in 
audit and reporting activities. 
Compliance rates improved 
dramatically over time and 
have remained at high levels. 
 
The goal was to improve 
compliance with established 
standards and hospital policy 
regarding PPE use by nurses 
administering chemo in the 
outpatient setting. 
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of the PPE, and continuous 
monitoring and feedback 
regarding performance. 
Hon et al. 
(2014)    
 




spectrometry.   
Active recruitment of 
participants via letter of 
invitation or telephone by 
members of research team. 
On-site surveys and self-
administration questionnaire. 
Setting: 5 hospitals and 1 
cancer treatment facility 
Sample: 115 participants/110 
supplied duplicate hand wipe 
sampling. Staff working in 
the process of flow of drug 
within a facility from initial 
delivery to waste disposal 
(8 groups of workers 
identified). 
Time Frame: not stated 
Results: 225 wipe 
samples/20% (n=44) were 
above the limit of detection 
(LOD) of 0.36ng per wipe. 
Average concentration per 






Unable to recruit 
housekeepers into study 
because the contract company 
that employs housekeepers 
declined to participate. 
The findings are only 
representative of the point in 
time when samples were 
collected. 
 
Samples were based on 
convenience sampling, which 
allowed assessment of 
exposure throughout the day, 
but does not allow 
comparison to task-based 
exposure levels. 
The purpose of the study was 
to determine the dermal 
contamination levels of 
healthcare employees 
working throughout the 
hospital and to identify 
factors that may influence 
dermal contamination. 
 
All worker categories had 
some level of dermal 
exposure. Highest level of 
dermal exposure was in 
administration units who 
were not responsible for drug 
administration (volunteers, 
oncologist, aide, dietician). 
Regardless of whether or not 
a worker received safe drug 
handling training, the 
proportion of samples above 
LOD was the same. 
Kang et al. 
(2017)    
 
Observational, descriptive 
study in 4 parts: a simulation 
observation, a survey (for 
both clinical and sim 
participants), and a follow-up 
evaluation simulation. 
Setting: University of 
Pittsburgh 
Sample: 82 HCP, 65 HCP 
(72.93%; including 3 HCP 
who participated in the 
clinical observation). 97% 
had at least 1 instance of 
contamination during the PPE 
doffing process in 2 sim 
sessions with a simple set and 





High likelihood of Hawthorne 
effect. Because convenience 
sample of study participants 
and PPE items from one 
health care system were 
adopted, these findings may 
Very little is known about 
how healthcare personnel 
actually use PPE. 
Evidence shows that 
traditional learning methods 
(e.g., watching educational 
videos, learning PPE 
guidelines) are inferior to 
immersive learning methods, 
including active learner 
involvement using 
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simulations, the 
contamination rate was 79% 
(n=103) 
Time Frame: August 31-
September, 2015 
Results: 
not be generalizable to other 
clinical settings. 
Camera lens and lighting may 




simulations that include 
feedback on performance. 
Contamination breaches 
appear to be associated with 
poor HCP PPE techniques, 
knowledge deficits, and 
behavior flaws. 
The study emphasized the 
need for refining PPE 
protocols based on further 
scientific evidence, 
reinforcing PPE training 
using innovative methods, 
improving and standardizing 
PPE equipment for targeting 
HCP optimal use. 
Lawson et al. 
(2019)    
 
Self-report questionnaire for 
pregnant nurses (within first 
20 weeks) and non-pregnant 
nurses (within the last 
month). 
Baseline NHS3 questionnaire. 
Setting: Online study 
Sample: 40,000 nurses 
participating in the Nurses’ 
Health Study born on or after 
January. 1, 1965  
Time Frame: Started in 2010 
and is ongoing 
Results:  
12% of non-pregnant 
nurses/9% pregnant nurses 
indicated they never wore 
gloves with HD admin, 
42%/38% never used a gown, 
32% who crushed HD pills 
did not wear gloves. 
Mean age/non-pregnant = 37 
years (SD 7.26) 
Mean age/pregnant = 29.5 





Did not collect info on the use 
of double versus single 
gloves, engineering controls, 
training of safe-handling 
practices, and reasons or 
barriers for not following 
safe-handling 
recommendations. 
No information on nurse 
specialties of respondents. 
No info on facility type or 
size, which might affect 
training personnel. 
The purpose of the study 
assessed glove and gown use 
by female pregnant and non-
pregnant nurses who 
administer antineoplastic 
drugs in the U.S. and Canada. 
 
Findings underscore the need 
for further training and 
education to ensure that both 
employers and nurses 
understand the risks involved 
and know which precautions 
will minimize such 
exposures. Adequate time 
must be allowed for worker to 
handle these drugs safely. 
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Yuki et al. 
(2013) 
 
Urine and wipe samples from 
patient and family members 
inside homes. 
Gas chromatography in 
tandem with mass 
spectroscopy-mass 




Setting: 3 patient homes 
Sample: 
Time Frame: 
Results: 35 and 16 urine 
samples were collected from 
the three patients and their 
family members. Drugs were 
detected in all samples.  
Cyclophosphamide (CP) in 8 
of 12 samples 5-FU exposure 





Sample size small 
Purpose: To measure the 
urinary excretion of Ads of 
three patients during 48 h 
after the admin of 
cyclophosphamide (2 
patients) and 5-FU (2 
patients) 
 
Home exposure was 
demonstrated. Findings 
indicate the importance of 
strict precautions by the 
members of treated cancer 
patients, as well as healthcare 
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Appendix C: Basic Steps of Compliance Flow Chart 
 

















Step 2:Identify the 
problem
Step 3: Define study 
methodology and 
criteria for evaluation
Step 4: Conduct the 
study as planned
Step 5: Analyze data: 
perpare summary of 
findings
Step 6: Compare data 
results with national 
benchmark/guidelines
Step 7: Design action 
plan based on results 
and FU to monitor 
actions implemented
Step 8: QIC presents 
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Appendix D: Signed Statement of Non-Research Determination 
 
Student Name: Cynthia D. Huff  
Title of Project:   USP <800> Compliance: A Hazardous Drug Safe-Handling PPE 
Toolkit for Infusion Nurses 
Brief Description of Project:  Hazardous drug (HD) residues pose a real threat to the 
health of staff, patients and families, and the environment when uncontrolled or 
mismanaged, especially in Cancer Centers (Hon, Teschke, Shen, Demers, & Venners, 
20150. Lack of diligent organizational and personal responsibility, and oversight in HD 
management have caused irreversible harm in some cases, and are well documented 
(Connor, Lawson, Polovich, & McDiarmid, 2014; Yuki, Sekine, Takase, Ishida, & 
Sessink, 2013).  Scientific evidence has demonstrated that harmful residues can 
contaminate commonly shared surfaces where HDs are administered, and patients may 
expose family members, pets, and their homes to residues for several days to weeks after 
chemotherapy treatment (Bohlandt, Sverdel, & Schierl, 2017; Yuki, et al., 2013).  
Healthcare organizations are preparing for the implementation of USP <800> (United 
States Pharmacopeial Chapter 800: Hazardous Drugs-Handling in Health Care Settings 
which imposes strict regulatory standards intended to protect health care workers from 
HD exposure beginning December 1, 2019. As USP <800> changes how HDs are 
handled, timely education and acceptance from health care personnel, especially 
pharmacists and nurses, will drive the long-anticipated worker protections (Andrews & 
Dill, 2018).  The purpose of an Ambulatory Care Hazardous Drug Safe-Handling PPE 
Toolkit for Infusion Nurses is to provide a resource toolkit that will improve nurses’ 
adherence to personal protective equipment (PPE) use, increase compliance with USP 
<800> Standards, and adhere to hospital policies and procedures for safe-handling.  
Better risk education is needed to ensure employers and health care workers are fully 
aware of the processes required to minimize exposure to these toxic drugs (Boiano, 
Steege, & Sweeney, 2014). There are six steps in the safe handling process for HDs: (1) 
Transport, (2) Receipt, (3) Storage, (4) Preparation, (5) Administration, and (6) Disposal 
of contaminated waste.  
    A) Aim Statement: By February 1, 2020, develop, implement, and evaluate a HD 
resource toolkit to improve adherence to personal protective equipment (PPE) use to 90% 
or higher with hazardous drug administration and with current hospital and USP <800> 
policies and procedures. 
   B) Description of Interventions: 
   1.  September, 2019 – Confidential observations of infusion nurses preparing, 
administering, and discarding HD waste will be completed by the DNP student (to 
determine the baseline level of adherence using an established tool called the “PPE 
Observation Tool” (Hennessy & Dynan, 2014).  A survey to obtain nurses’ self-
assessments of adherence to policies and USP <800> will be provided to the AIC 
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nurses via Qualtrics. 
   2.  October, 2019 – An expert panel will introduce the Hazardous Drug Safe-
Handling PPE Toolkit to staff and bring awareness of the health risks with HD 
exposure, and explore barriers for self-adherence in the practice environment.  
Ambulatory Infusion Center (AIC) nurses will attend a two-hour skills session to 
introduce them to the proper donning and doffing of PPE and the policies and 
procedure changes related to mandatory requirements imposed by USP <800>. 
   3.  November, 2019 – Individual nurse observations will be performed to assess for 
PPE adherence and compared to the self-assessment survey results to reinforce USP 
<800> standards and hospital policies and procedures for safe-handling and protections 
using the “Safe-Handling Adherence Between Observation and Self-Assessment tool.”  
A “Hazardous Drug Administration Safe Handling Checklist” (Peer-to-Peer Feedback 
tool) will be utilized to educate and reinforce goal 90% PPE compliance for all nurses 
handling HDs (Polovich & Olsen, 2017). 
   4.  December, 2019 – Data will be collected pre-and-post intervention, analyzed, and 
displayed for staff on the performance dashboard as a quality improvement project.  
5. January and February, 2020 – DNP student will present results to the respective 
committees and enter the results in the Cancer Committee’s minutes to fulfill the COC 
Standard 4.8 requirements. 
C) How will this intervention change practice?  
The Hazardous Drug Safe-Handling PPE Toolkit intervention is expected to improve 
nurses’ access to USP <800> PPE requirements and improve adherence and 
compliance with the organization’s policy and procedures for HD safe-handling.  
D) Outcome measurements:  
   1.  Monthly peer-to-peer audit tool and real-time feedback indicate 90% or higher 
adherence and compliance with PPE use during hazardous drug administration 
processes. 
   2.  Pre-and-post intervention analysis posted on performance dashboard for staff 
review and comments. 
   3.  100% compliance with USP <800> PPE expectations during hazardous drug 
administration as evidenced by internal audit from oncology infusion nurses, quality 
and risk management department managers, and nursing education audits annually. 
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To qualify as an Evidence-based Change in Practice Project, rather than a Research Project, the 
criteria outlined in federal guidelines will be used: (http://answers.hhs.gov/ohrp/categories/1569)  
x   This project meets the guidelines for an Evidence-based Change in Practice Project as 
outlined in the Project Checklist (attached). Student may proceed with implementation. 
☐This project involves research with human subjects and must be submitted for IRB approval 
before project activity can commence. 
Comments: 
EVIDENCE-BASED CHANGE OF PRACTICE PROJECT CHECKLIST * 
Instructions: Answer YES or NO to each of the following statements: 
 
Project Title:  
USP <800> Compliance: Hazardous Drug Safe-Handling Toolkit for Infusion 
Nurses 
YES NO 
The aim of the project is to improve the process or delivery of care with 
established/ accepted standards, or to implement evidence-based change. There is 
no intention of using the data for research purposes. 
X  
The specific aim is to improve performance on a specific service or program and is 
a part of usual care.  ALL participants will receive standard of care. 
X  
The project is NOT designed to follow a research design, e.g., hypothesis testing 
or group comparison, randomization, control groups, prospective comparison 
groups, cross-sectional, case control). The project does NOT follow a protocol that 
overrides clinical decision-making. 
X  
The project involves implementation of established and tested quality standards 
and/or systematic monitoring, assessment or evaluation of the organization to 
ensure that existing quality standards are being met. The project does NOT 
develop paradigms or untested methods or new untested standards. 
X  
The project involves implementation of care practices and interventions that are 
consensus-based or evidence-based. The project does NOT seek to test an 
intervention that is beyond current science and experience. 
X  
The project is conducted by staff where the project will take place and involves 
staff who are working at an agency that has an agreement with USF SONHP. 
X  
The project has NO funding from federal agencies or research-focused 
organizations and is not receiving funding for implementation research. 
X  
The agency or clinical practice unit agrees that this is a project that will be 
implemented to improve the process or delivery of care, i.e., not a personal 
research project that is dependent upon the voluntary participation of colleagues, 
students and/ or patients. 
X  
If there is an intent to, or possibility of publishing your work, you and supervising 
faculty and the agency oversight committee are comfortable with the following 
statement in your methods section: “This project was undertaken as an Evidence-
based change of practice project at X hospital or agency and as such was not 
formally supervised by the Institutional Review Board.”  
X  
 
USP <800> AND THE PPE PROJECT   53 
 
ANSWER KEY: If the answer to ALL of these items is yes, the project can be considered an 
Evidence-based activity that does NOT meet the definition of research.  IRB review is not 
required.  Keep a copy of this checklist in your files.  If the answer to ANY of these questions 
is NO, you must submit for IRB approval. 
 
*Adapted with permission of Elizabeth L. Hohmann, MD, Director and Chair, Partners Human 
Research Committee, Partners Health System, Boston, MA.   
STUDENT NAME (Please print):  
Cynthia Huff 
Signature of Student:  
______________________________________________________DATE____________         
 
SUPERVISING FACULTY MEMBER (CHAIR) NAME (Please print):   
 
________________________________________________________________________ 
Signature of Supervising Faculty Member (Chair):  
______________________________________________________DATE____________ 
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Appendix E: Gap Analysis 
 
1. The physical layout of the treatment areas lend difficulty with hazardous drug (HD) 
administration. 
2. The AIC is not set up for moderate HD disposal; there are gaps in pharmaceutical waste 
management (i.e. PPE). 
3. Policies and procedures do not reflect USP <800> requirements for HD processes and 
require modifications for AIC compliance with PPE management and waste disposal. 
4. The cost impact for meeting the USP <800> Standards are unknown because the nurses 
in the AIC are not wearing required PPE except for one pair of nitrile gloves. 
5. There is no standard work for HD administration in the AIC. 
6. There are gaps in pharmaceutical delivery of HDs to the nurses (need to be delivered in 
specific HD bins and stored in cabinets in the medication rooms, not on countertops in 
patient areas). 
7. There is no system-defined comprehensive list of HDs for the AIC (NIOSH List of 
Hazardous Drugs is the default), and there is no risk assessment for all HDs. 
8. No annual PPE training or learning modules for HD administration. 
9. There are space limitations within the treatment area for donning and doffing PPE in the 
designated patient threshold areas. 
10. Adherence and compliance with PPE have been ignored for several years in the AIC, and 
nurses’ beliefs and attitudes that exposure risks are minimal and do not warrant changing 
behavior with HD administration. 
11. Scheduling demands and workload pressures do not reflect the appropriate acuity levels 
of patient appointment times and unique situations. 
12. There are inconsistent HD labeling on medications delivered by the pharmacy. 
13. Tools needed to assess for PPE compliance, such as observation tools or Standard work 
for “HD Safe Handling” are unavailable in the AIC. 
14. No staff champions to promote best practice with PPE use. 
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Appendix F: Gantt Chart 
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1.1 Initiation 1.1.1 Evaluation and Recommendations 
1.1.2 Develop Project Charter 
1.1.3 Deliverable: Submit Project Charter 
1.1.4 USP <800> Committee Reviews Project Charter 
1.1.5 Project Charter Signed/Approved 
1.2 Planning 1.2.1 Create Preliminary Scope Statement 
1.2.2 Determine Project Team 
1.2.3 Project Team Kickoff Meeting 
1.2.4 Develop Project Plan 
1.2.5 Submit Project Plan 
1.2.6 Milestone: Project Plan Approval 
1.3 Execution 1.3.1 Project Kickoff Meeting 
1.3.2 Verify & Validate USP <800> PPE Requirements 
1.3.3 Develop/Organize HD PPE Toolkit 
1.3.4 Decide on Specific Type/Amount of PPE per unit 
1.3.5 Testing Phase in Ambulatory Infusion Center 
         (AIC) 
1.3.6 Completed Toolkit Introduced in AIC 
1.3.7 Staff Training 
1.3.8 Go Live 
1.4 Control 1.4.1 Project Management 
1.4.2 Project Status Meetings 
1.4.3 Risk Management 
1.4.4 Update Project Management Plan 
1.5 Closeout 1.5.1 Audit Procurement 
1.5.2 Document Lessons Learned 
1.5.3 Update Files/Records 
1.5.4 Gain Formal Acceptance 
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Element Name Definition 
1 1 Personal Protective Equipment 
(PPE) Toolkit Implementation in 
Ambulatory Care 
All work to implement the new toolkit in 
Ambulatory Care Setting. 
2 1.1 Initiation The work to initiate the project. 
3 1.1.1 Evaluation and Recommendations Working group to evaluate USP <800> 
General Chapter PPE requirements and make 
recommendations for the Ambulatory Care 
Setting. 
3 1.1.2 Develop Project Charter Project Manager to develop the Project 
Charter. 
3 1.1.3 Deliverable: Submit Project Charter Project Charter is delivered to USP <800> 
Committee designee. 
3 1.1.4 USP <800> Committee Reviews 
Project Charter 
USP <800> Committee Reviews Project 
Charter. 
3 1.1.5 Project Charter Signed/Approved The USP <800> Committee signs the Project 
Charter which authorizes the Project 
Manager to move to the Planning Process. 
2 1.2 Planning The work for the planning process for the 
project. 
3 1.2.1 Create Preliminary Scope Statement Project Manager creates a Preliminary Scope 
Statement. 
3 1.2.2 Determine Project Team The Project Manager determines the project 
team and requests the resources. 
3 1.2.3 Project Kickoff Meeting The planning process is officially started 
with a project kickoff meeting which 
includes the Project Manager, Project Team 
and USP <800> Committee designee. 
3 1.2.4 Develop Project Plan Under the direction of the Project manager, 
the team develops the project plan. 
3 1.2.5 Submit Project Plan Project Manager submits the project plan for 
approval. 
3 1.2.6 Milestone: Project Plan Approval The project plan is approved and the Project 
Manager has permission to proceed to 
execute the project according to the project 
plan. 
2 1.3 Execution Work involved to execute the project. 
3 1.3.1 Project Kickoff Meeting Project Manager conducts a formal kickoff 
meeting with the project team, project 
stakeholders, and USP <800> Committee 
designee. 
3 1.3.2 Verify & Validate USP <800> PPE 
Requirements 
The original USP <800> General Chapter 
requirements for personal protective 
equipment (PPE) use with hazardous drug 
agents is reviewed by the Project Manager 
and team, then validated with the 
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stakeholders. This is where additional 
clarification may be needed. 
3 1.3.3 Develop/Organize HD PPE Toolkit The resources to design the new PPE toolkit 
will be assembled. 
3 1.3.4 Decide on Specific Type/Amount of 
PPE per Unit 
The procurement of all PPE required for the 
project. 
3 1.3.5 Testing Phase in Ambulatory 
Infusion Center 
Team creates a system for testing PPE 
adherence and customizations of user 
interfaces (Low, Moderate, High Risk) with 
hazardous drug handling. 
3 1.3.6 Completed PPE Toolkit introduced 
into Ambulatory Infusion Center 
setting 
The actual PPE Toolkit is introduced into the 
Ambulatory Infusion Center’s workflow 
processes. 
3 1.3.7 Staff Training All staff are provided with a one-hour 
training on donning and doffing of PPE. 
Additionally, managers are provided with a 
two-hour class to cover advanced reporting. 
3 1.3.8 Go Live System goes live with all Ambulatory 
Infusion Center (AIC) staff. 
2 1.4 Control  The work involved for the control process of 
the project. 
3 1.4.1 Project Management Overall project management for the project. 
3 1.4.2 Project Status Meetings Weekly team status meetings. 
3 1.4.3 Risk Management Risk management efforts as defined in the 
Risk Management Plan. 
3 1.4.4 Update Project Management Plan Project Manager updates the Project 
Management Plan as the project progresses. 
2 1.5 Closeout The work to close out the project. 
3 1.5.1 Audit Procurement An audit of all measurement tools and 
management plans procured for the project, 
ensure that all procured products are 
accounted for and in the asset management 
system. 
3 1.5.2 Document Lessons Learned Project Manager along with the project team 
performs a “lessons learned” meeting and 
documents the lessons learned from the 
project. 
3 1.5.3 Update Files/Records All files, data, and adherence monitoring 
tools are updated to reflect the completed 
PPE Toolkit intervention. 
3 1.5.4 Gain Formal Acceptance The USP <800> Committee formally accepts 
the project by signing the acceptance 
document included in the project plan. 
3 1.5.5 Archive Files/Documents All project related files and documents are 
formally archived. 
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Ambulatory Care refers to medical services performed on an outpatient basis, 
without admission to a hospital or other facility. Ambulatory care is provided in 
settings such as dialysis clinics, ambulatory infusion centers, ambulatory surgical 




In pharmacology, hazardous drugs are drugs that are known to cause harm, 
which may or may not include genotoxicity (the ability to cause a change or 
mutation in genetic material). These drugs can be classified as antineoplastic, 
cytotoxic agents, biologic agents, antiviral agents and immunosuppressive 
agents. The NIOSH criteria include: carcinogenicity, teratogenicity, reproductive 
toxicity, genotoxicity, organ toxicity at low doses, and drugs that mimic existing 
drugs in structure or toxicity. 




Personal protective equipment is protective clothing, headwear, goggles, gloves, 
shoe covers, respirators, or other garments or equipment designed to protect the 
wearer’s body from injury, infection, or exposure to hazardous agents. The 
hazards addressed by protective equipment include physical, electrical, heat, 
chemicals, biohazards, and airborne particulate matter. 
PPE Toolkit A set of resources, interventions, and skills required to ensure staff adherence to 
hazardous drug safe-handling and compliance with USP General Chapter <800> 
requirements for PPE selection and use during transport, receivership, storage, 





Protects any worker in contact with hazardous drugs or the patient environment 
and includes, but not limited to; pharmacists; technicians, nurses, physicians, 
physician assistants, nurse practitioners, home health care, environmental 
services workers, engineering, anyone entering a patient treatment area, 
pharmacies, hospitals, and other healthcare institutions, patient treatment clinics, 
physician practices, and the public. 
WBS Code A unique identifier assigned to each element in a Work Breakdown Structure for 
the purpose of designating the elements hierarchical location within the WBS. 
WBS Component A component of a WBS which is located at any level.  It can be a Work Package 
or a WBS Element as there’s no restriction on what a WBS Component is. 
WBS Element A WBS element is a single WBS component and its associated attributes located 
anywhere within a WBS. A WBS Element can contain work, or it can contain 
other WBS Elements or Work Packages. 
Work Package A Work Package is a deliverable or work component at the lowest level of its 
WBS branch. 
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Appendix J: Responsibility/Communication Matrix 
 
Who What How 
Cancer Committee Members Evaluation and Recommendations Monthly at Cancer Committee meeting 
Assistant Unit Manager (AUM) AIC Develop Project Charter Discuss project with leadership and ask for 
recommendations of persons interested in 
working on the PPE Project Team 
Assistant Unit Manager (AUM) AIC Submit Project Charter Meet with interested people and gain buy-in 
and have them help finalize the Charter and 
AUM will send completed Charter to USP 
<800. Committee 
USP <800> Committee USP <800> Committee Reviews Project 
Charter 
Present at USP <800> Committee meeting 
and request approval from Project Sponsor 
USP <800> Committee/Cancer Committee Project Charter Approved Committee will approve Charter and report 
back to DNP team 
Cancer Committee 
NPs/Pharmacy/AUM/Clinical Nurse Educator 
Create Preliminary Scope Statement Meeting with the group to discuss the needs 
of the Cancer Center related to physician 
practices/specialties 
Assistant Unit Manager Determine Project Team AUM to meet with interested persons and 
select based on knowledge and skills related 
to HD management and PPE knowledge 
Project Charter Team Members Project Team Kickoff Meeting Arrange for meeting with group once Charter 
has been approved via Skype or Zoom 
sessions 
Assistant Unit Manager (AUM) Submit Project Plan AUM to assist team with project plan and 
submit to USP<800> committee 
Cancer Committee Members/ Executive 
Director Cancer Center 
Milestone: Project Plan Approval Report back to Cancer Committee and gain 
approval at next meeting 
USP <800> PPE Group Project Kickoff Meeting Notify PPE group of plans to set up meeting 
by email and personal telephone calls 
Clinical Nurse Educator 
Pharmacy Department 
USP <800> Committee Representative 
Verify & Validate USP <800> Requirements Check with OSHA, NIOSH, and USP<800> 
Committee to confirm requirements for PPE 
Clinical Nurse Educator/ DNP Student (AUM 
in AIC) 
Develop/Organize HD PPE Toolkit Review current evidence regarding toolkit 
resources for HD PPE/select tools/request 
permission from owners of tools to use 
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Clinical Nurse Educator/ DNP Student 
Relief Charge Nurses in AIC/Central Supply 
Department 
Decide on Specific Type/Amount of PPE per 
unit 
Request items used for PPE and bring to unit 
for evaluation by nurses/discuss preferences 
and select type and amount needed for test 
phase 
Clinical Nurse Educator/DNP Student Testing Phase in AIC Preliminary testing with one RC to determine 
feasibility of project and to demonstrate 
“Observation of PPE Tool” purpose and 
planned confidential use 
NPs, Pharmacist, AUM Confidential Observations in AIC Audits over 2 weeks at random intervals by 
practitioners, pharmacy, and AUM during 
routine rounding in AIC 
Oncology MD, NPs, Pharmacist, OCN Nurse, 
Oncology Nurse Educator, AUM 
Educational Intervention by Panel Select panel of experts to introduce HD 
education and need for PPE/invite to 
informational meeting about project 
DNP Student/ Clinical Nurse Educator Completed Toolkit introduced in AIC Review final Tools for the toolkit and get 
approval from Executive Director and expert 
panel members to proceed with 
printing/preparing for intervention 
RN Staff in AIC Staff Training-Peer-to-Peer Review Provide inservice during monthly staff 
meeting to teach use of peer-to-peer review 
tool for PPE during administration 
All Staff in AIC Go Live Use huddle boards, email, and text reminders 
of Go Live with PPE date 
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Appendix K: SWOT Analysis 
 
Strengths 
• Expert Oncology Staff Resources 
• Infusion-Trained Chemotherapy Certified 
RN Team 
• Supportive Leadership 
• Long-term Employees at the facility 
committed to quality improvement at all 
levels 
• Teamwork between various 
divisions/pharmacy/physician offices and 







• Room design and waste management not 
practical for effective safe-handling 
• Employee and environmental surveillance 
inconsistently performed and costly 
• Policies and procedures reflect guidance 
for PPE use, not mandatory (open to 
interpretation by staff nurses) 
• Unknown cost impact for meeting the 
USP <800> Standards for PPE use 
• No system-defined comprehensive list of 
HDs, and no risk assessment for all HDs 
• No standard work process for PPE 
utilization with HD administration 
• Beliefs and attitudes of nurses that PPE is 
a personal choice 
• No audit tools to measure compliance 
with USP <800> Standards for PPE use 
Opportunities 
• Increase in demand for ambulatory 
infusion services across the country 
requires more oncology-infusion trained 
nurses/may need to partner with nursing 
schools to provide exposure/hiring pool 
for future needs 
• Decrease the gap between leadership and 
frontline infusion nurses to improve care 
delivery and patient/nurse safety in the 
AIC 
• Increase in the ageing population with 
baby boomers at Medicare age 
• Increase all infusion nurses training on 
chemotherapy/biotherapy/infusion 
therapy for future growth needs 
 
Threats 
• Unknown costs associated with PPE 
equipment, environmental testing for 
residues, and health monitoring of staff 
for HD exposure/no known HD limits like 
radiation oncology practice 
• Maintaining and recruiting nurses to work 
in high-risk exposure environment 
• Decrease in funding for infusion services 
with 21st Century Cures Act. Political 
climate related to healthcare structural 
changes within the political parties as to 
what changes will be implemented 
• Deadline extended for implementation of 
USP <800> regulations 
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Appendix L: Proposed Budget 
 
Type of Expense Cost 
Staff Training on “Observation of PPE Use Tool” 
(NP, CNL, Clinical Nurse Educator, Pharmacist) 
– 1 hour discussion 
$75/hr. x 7 persons = $525 
 
Staff Training on “Hazardous Drug 
Administration Safe-Handling Checklist Tool” (1 
Clinical Nurse Educator, 2 Relief Charge Nurses, 
2 Nurse Practitioners, 2 Pharmacists) 
$75/hr. x 7 persons = $525 
 
Expert Panel Discussion for Staff Complimentary Time from Cancer Committee 
Budget 
($1,200 in kind) 
Staff training estimate based on $75 (15 nurses) 2-
hour training 
$2,250 
USP <800> Compliance: Hazardous Drug Toolkit 
for Infusion Nursing (printing) 
$1,000 
DNP Project Manager = 30 hrs. $75/hr. x 30 hrs. = $2,250 
PPE Supplies including White Preparation trays in 
Medication Rooms 
Average 5 RNs per day x 10 hrs. = 50 hrs. 
Average nurse # PPE changes per patient (5) x 15 
PPE changes per day 
$15 per PPE Kit x 15 changes/per nurse/per shift 
= $210 
x 5 nurses/per day = $1,050 per day x 7 
days/week = $7,350 per week 
Hazardous Waste Bins for PPE and Medical 
Waste Disposal per cubicle (35) 
$35 per waste bin x 35 cubicles = $1,225 per 
week 
Additional Workers Compensation Funds for 
medical monitoring, HD exposure treatment, and 
long-term medical management 
Currently under review/organization is self-
insured and committed to employee safety 
measures to manage risk. 
Estimated Total $16,385 + ($1200 in kind) 
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Appendix M: IRB Approval 
 
To ensure Internal Review Board (IRB) approval is not required for implementation of  
the QI project, I will submit the DNP Statement of Non-Research Determination form to my 
DNP Committee (see Appendix D), as well as submit a request for project review to the 
healthcare systems’ IRB committee.
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Appendix N: Letter of Support from Organization 
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Appendix P: Dummy Tables 
 
Table 1: PPE Observation Tool 
 
Location: 
Month/ Year: ______________   
Observer:  ________________ 
                  
Observation: Compliant with USP 
<800> Hospital Policy 
































• Handling bags or syringes 
outside the leak-proof 
transport bag requires gloves 
and gowns 
• Handling the closed, zipped 
leak-proof bag does not 
require gown (gloves are 
optional). 
          
Administration 
• Hanging bags, attaching 
tubing, administering IVP, 
IM, and SC requires gloves 
and gown. 
          
Discard 
• Take down of bags and tubing 
that contain or contained 
chemotherapy and discarding 
syringes after IVP, IM, and 
SC requires gown gloves and 
gown. 
          
Description of Non-Compliance           
Wore no gloves           
Wore non-chemotherapy gloves           
Wore no gown           
Reused gown           
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PPE gown worn in non-patient care 
area 
          
Chemotherapy at desk or in the non-
patient care area 








IM – Intramuscular; IVP – Intravenous Push; PPE – personal protective equipment; SC – subcutaneous 
Note: For each observation, please indicate “yes” for compliant with safe-handling policy or “no” if not compliant. If “no”, check the corresponding box 
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Table 2: Observations of Chemotherapy Safe-Handling Adherence in Number of Events 
Behavior Adherence (n) Observation (n) 
Handling   
Uses absorbent pad on work surface for chemotherapy 
agents 
  
Wears one pair of chemotherapy-approved gloves to 
remove chemotherapy agents from transport bag 
  
Wears two pairs of chemotherapy-approved gloves to 
remove chemotherapy agents from transport bag 
  
Removes outer gloves prior to programming pump   
Washes hands   
Wears second pair of chemotherapy-approved gloves over 
ribbed cuff of gown 
  
Removes gown prior to leaving room   
Wears chemotherapy-approved gown, with first pair of 
approved gloves under ribbed cuff of gown 
  
Disposes of gloves in a chemotherapy-approved container 
after initiating chemotherapy 
  
Disconnecting and discarding   
Removes gown prior to leaving room   
Wears two pairs of chemotherapy-approved gloves and 
chemotherapy-approved gown when handling 
chemotherapy 
  
Wraps gauze pad around connection site (CSTD) when 
disconnecting chemotherapy tubing, leaving chemotherapy 
bag attached 
  
Disposes of gloves in a chemotherapy-approved container   
Washes hands   
Discards the chemotherapy bag and attached secondary 
tubing in chemotherapy-approved waste container 
  
(Colvin, Karius, & Albert, 2016) 
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Table 3: Safe-Handling Adherence between Observation and Self-Assessment 
Behavior Observation Adherence       Self-Assessment Adherence 
N            N           %                         N              %             p 
Double gloved during administration        
Removed outer gloves prior to 
programming pump 
       
Washed hands after glove removal 
post-administration 
       
Double gloved during disconnect 
 
       
Wrapped gauze pad around connection 
site 
       
Removed gown prior to leaving room 
at disconnect 
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Name: _____________________________Date of Review: _________    Pt MR #: ________________ 
PRIOR TO ADMINISTRATION YES NO INITIALS 
1. Gather equipment required for drug administration.    
2. Select appropriate gloves for hazardous drug administration.    
3. Select appropriate gown for hazardous drug administration.    
4. Identify situations when mask and face protection are required.    
5. Locate hazardous drug spill kit.    
6. Obtain hazardous waste container.    
ADMINISTRATION    
1. Wash hands and don personal protective equipment before opening drug 
delivery bag. 
   
2. Visually inspect the contents of the delivery bag for leaks.    
3. Gather IV administration supplies including closed-system drug-transfer 
devices. 
   
4. For IV infusions 
• Ensure tubing is primed with a nondrug solution. 
• Utilize plastic backed absorbent pad under work areas. Remove cap from IV 
tubing and connect to patient’s IV device. 
• Utilize closed-system drug-transfer device when compatible. 
• Tighten locking connections. 
• When complete, don personal protective and discontinue IV bag with tubing 
intact (do not unspike bag). 
• Utilize gauze pads when disconnecting from patient’s IV device when a 
closed-system drug-transfer device cannot be used. 
   
5. For IV push medications 
• Utilize closed-system drug-transfer device when possible. 
• Tighten locking connection. 
• When complete, do not recap needle. 
• Discard syringe-needle unit in puncture-proof container. 
 
   
6. For intramuscular/subcutaneous injections 
• Utilize closed-system transfer-device when possible. 
• Attach needle to syringe. 
• Tighten locking connection. 
• When complete, do not recap needle. 
• Discard syringe-needle unit in puncture-proof container. 
   
7. For oral drugs (tablets/capsules) 
• If using bar code technology, scan medication prior to removing medication 
from packaging. 
• Don gloves. 
• Open unit-dose package and place into medicine cup (avoid touching drug or 
inside of package). 
• Avoid touching tablets/capsules. 
   
8. For oral drugs in liquid form 
• Obtain drug in final form in appropriate oral syringe. 
• Don double gloves, gown, and mask with face protection 
• Use plastic-backed absorbent pad during administration. 
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• Discard syringe in hazardous waste container after administration. 
POST-ADMINISTRATION    
1. Don personal protective equipment.    
2. Seal hazardous drug-contaminated supplies in sealable plastic bag for 
transport to hazardous waste container. 
   
3. Place sealed plastic bag in hazardous waste container.    
4. Remove outer gloves.    
5. Close lid on waste container.    
6. Decontaminate equipment in the area appropriately.    
7. Remove and discard inner gloves.    
8. Wash hands thoroughly with soap and water.    
 
 











(Polovich & Olsen, 2017) 
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Appendix Q: Key Elements of the Toolkit 
 
(LAMINATED FLIPCHART FORMAT) 
 
 















FOR FRONT LINE 
CLINICANS
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